IPSEN (OTCMKTS:IPSEY) Sees Strong Trading Volume – What’s Next?

IPSEN (OTCMKTS:IPSEY) shares saw unusually-strong trading volume on Monday . 5,114 shares were traded during trading, an increase of 134% from the previous session’s volume of 2,190 shares.The stock last traded at $48.13 and had previously closed at $46.50.

Analysts Set New Price Targets

IPSEY has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Zacks Research raised shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

IPSEN Price Performance

The business has a fifty day moving average price of $47.13 and a 200 day moving average price of $44.10.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).